Levofloxacin and sparfloxacin: New quinolone antibiotics

Annals of Pharmacotherapy

Volumn 32, Issue 3, 1998, Pages 320-336

  Martin, Steven J ^a   Meyer, Joette M ^b   Chuck, Susan K ^b   Jung, Rose ^b   Messick, Chad R ^b   Pendland, Susan L ^b  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Fluoroquinolones; Levofloxacin; Sparfloxacin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; DOXYCYCLINE; ENOXACIN; ERYTHROMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; NEW DRUG; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CHLAMYDIA; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GONOCOCCAL URETHRITIS; HAEMOPHILUS INFLUENZAE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NAUSEA; NONSPECIFIC URETHRITIS; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; VOMITING;

ABSORPTION; ANTI-INFECTIVE AGENTS; BRONCHITIS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; OFLOXACIN; PNEUMONIA; QUINOLONES; SINUSITIS; SKIN DISEASES; URINARY TRACT INFECTIONS;

EID: 0031886261     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17178     Document Type: Review

References (149)

1. Morrissey I, Hoshino K, Sato K, Hayakawa I, Bures MG, Shen LL. Mechanisms of differential activites of ofloxacin enantiomers. Antimicrob Agents Chemother 1996;40:1775-84.
2. Bryskier A, Chantot J-F. Classification and structure-activity relationships of fluoroquinolones. Drugs 1995;49(suppl 2):16-28.
3. Cozzarelli NR. DNA gyrase and the supercoiling of DNA. Science 1980; 207:953-60.
4. Smith JT, Lewin CS. Chemistry and mechanisms of action of the quinolone antibacterials. In: Andriole VT, ed. The quinolones. New York: Academic Press, 1988:23-82.
5. Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanism of action and resistance to ciprofloxacin. Am J Med 1987;82(suppl 4a):12-20.
6. Fuchs PC, Barry AL, Pfaller MA, Allen SD, Gerlach EH. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 1991;35:764-6.
7. Bauernfeind A. Comparative in-vitro activities of the new quinolone, BAY y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother 1993;31:505-22.
8. Chin N-X, Gu J-W, Yu K-W, Zhang Y-X, Neu HC. In vitro activity of sparfloxacin. Antimicrob Agents Chemother 1991;35:567-71.
9. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, et al. In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992;36: 860-6.
10. Dholakia N, Rolston RV, Ho DH, LeBlanc B, Bodey GP. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 1994;38:848-52.
11. Jones RN, Barrett MS, Erwin ME, Briggs BM, Johnson DM. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds. Diagn Microbiol Infect Dis 1991;14:319-30.
12. Louie A, Baltch AL, Ritz WJ, Smith RP. Comparative in vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD-131501) and reference antimicrobial agents. J Antimicrob Chemother 1991;27:793-9.
13. Rolston KV, Messer M, Ho DH. Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer. Antimicrob Agents Chemother 1990; 34:1812-3.
14. Pankuch GA, Jacobs MR, Applebaum PC. Susceptibilites of 123 Xanthomonas maltophilia strains to clinafloxacin, PD-131628, PD-138312, PD-140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother 1994;38:369-70.
15. Lecso-Boret M, Pierre J, Sarkis-Karam D, Lubera S, Bergogne-Berezin E. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother 1992;36:669-71.
16. Vartivarin S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994; 38:624-7.
17. Spangler SK, Visall MA, Jacobs MR, Applebaum PC. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob Agents Chemother 1996;40:772-5.
18. Canton E, Peman J, Jimenez T, Ramon MS, Gobernado M. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 1992;36:558-65.
19. Cormican MG, Erwin ME, Marshall SA, Jones RN. Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1996;24:155-60.
20. Crokaert F, Aoun M, Duchateau V, Grenier P, Vandermies A, Klastersky J. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. Eur J Clin Microbiol Infect Dis 1996;15:696-8.
21. Neu HC, Chin N-X. In vitro activity of S-ofloxacin. Amimicrob Agents Chemother 1989;33:1105-7.
22. Eliopoulos GM, Wennersten CB, Moellering RC Jr. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn Microbiol Infect Dis 1996;25:35-41.
23. Barry AL, Fuchs PC. Antistaphylococcal activity of the fluoroquinolones CI-960, PD131628, sparfloxacin, ofloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991;10:168-71.
24. Louie A, Baltch AL, Ritz WJ, Smith RP. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria. Chemotherapy 1991;37:275-82.
25. Smith KR, Cobbs CG. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 1992;11: 55-8.
26. Scheel O, Lyon DJ, Rosdahl VT, Adeyemi-Doro FAB, Ling TKW, Cheng AFB. In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993. J Antimicrob Chemother 1996;37: 243-51.
27. Rotstein C, Amsterdam D, Beam TR Jr, Mandell LA, Gorzynski EA. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci. Diagn Microbiol Infect Dis 1993;17:85-91.
28. Miranda AG, Wanger AR, Singh KV, Murray BE. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother 1992;36:1325-8.
29. Pankuch GA, Jacobs MR, Applebaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995;35: 230-2.
30. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, WIN 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992;36:856-9.
31. Loo VG, Lavellee J, McAlear D, Robson HG. The in-vitro susceptibilities of 326 Streptococcus pneumoniae isolates to nine antimicrobial agents including penicillin and newer quinolones. J Antimicrob Chemother 1994;33:641-5.
32. Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Heifetz CL. In vitro activity of sparfloxacin (CI-978, AT-4140, PD 131501). A quinolone with high activity against gram-positive bacteria. Diagn Microbiol Infect Dis 1991;14:403-15.
33. Perri MB, Chow JW, Zervos MJ. In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1993;17:151-5.
34. Borobio MV, Conejo MC, Ramirez E, Suarez AI, Perea EJ. Comparative activities of eight quinolones against members of the Bacteroides fragilis group. Antimicrob Agents Chemother 1994;38:1442-5.
35. Goldstein EJ, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992;36:1158-62.
36. Aldridge KE. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 1994;38:1671-4.
37. Cohen MA, Yoder SL, Talbot GH. Sparfloxacin worldwide in vitro literature: isolate data available through 1994. Diagn Microbiol Infect Dis 1996;25:53-64.
38. Klugman KP, Capper T, Bryskier A. In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother 1996;40:2802-4.
39. Hayden MK, Matushek MG, Trenholme GM. Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species. Diagn Microbiol Infect Dis 1995;22:349-52.
40. Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother 1990;26:667-76.
41. Bajaksouzian S, Visalli MA, Jacobs MR, Applebaum PC. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against Acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother 1997;41:1073-6.
42. Bauerfeind A. Comparative in-vitro activities of the new quinolone, BAY y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother 1993;31:505-22.
43. Malmborg AS, Ahlen S. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract infections. Chemotherapy 1993;39:32-5.
44. Rudrik JT, Ferrigno SR, Gee SL. In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone agent, against Haemophilus and gram-positive cocci. Diagn Microbiol Infect Dis 1991;14:355-60.
45. Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob Agents Chemother 1991;35:1181-5.
46. Nakata K, Maeda H, Fujii A, Arakawa S, Umezu K, Kamidono S. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrob Agents Chemother 1992;36:188-90.
47. Perea EJ, Aznar J, Garcia-Iglesias MC, Pascual A. Comparative in-vitro activity of sparfloxacin against genital pathogens. J Antimicrob Chemother 1996;37(suppl A):19-25.
48. Lefevre JC, Bauriaud R, Gaubert E, Escaffre MC, Lareng MB. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens. Chemotherapy 1992;38:303-7.
49. Cooper MA, Baldwin D, Matthews RS, Andrews JM, Wise R. In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics. J Antimicrob Chemother 1991;28:407-13.
50. Martin DH, Cammarata CL, Grubb D. In vitro activity of sparfloxacin (C1-978, AT-4140), ofloxacin, doxycycline, and tetracycline versus genital tract mycoplasmas and Chlamydia trachomatis. Eur J Microb Infect Dis Special Issue, 1991:563-4.
51. Edelstein PH, Edelstein MA, Lehr KH, Ren J. In-vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996;37:117-26.
52. Jones RN. Activity of sparfloxacin (AT-4140), PD127391 and PD-131628 against Legionella spp. J Antimicrob Chemother 1991;27: 389-96.
53. Hammerschlag MR, Qumel KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-4.
54. Roblin PM, Montalban G, Hammerschlag MR. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1994;38:1402-3.
55. Kaku M, Ishida K, Irifune K, Mizukane R, Takemura H, Yoshida R, et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:738-41.
56. Kenny GE, Cartwright FD. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrob Agents Chemother 1991;35:587-9.
57. Yew WW, Piddock LJV, Li MSK, Lyon D, Chan CY, Cheng AFB. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994;34:343-51.
58. Ji B, Lourds N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:134-4.
59. Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:1610-6.
60. Klopman G, Wang S, Jacobs MR, Bajaksouzian S, Edmonds K, Ellner JJ. Anti-Mycobacterium avium activity of quinolones: in vitro activities. Antimicrob Agents Chemother 1993;37:1799-806.
61. Barrett MS, Jones RN, Erwin ME, Koontz FP. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellulare complex, M. chelonae, and M. fortuitum. Diagn Microbiol Infect Dis 1992;15:169-71.
62. Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levofloxacin against nontubetculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 1996;40:2483-7.
63. Rastogi N, Goh KS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1991;35:1933-6.
64. Skinner PS, Furney SK, Kleinert DA, Orme IM. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:750-3.
65. Yajko DM, Sanders CA, Nassos PS, Hadley WK. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Antimicrob Agents Chemother 1990;34:2442-4.
66. Piddock LJV. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 1995;49(suppl 2):29-35.
67. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
68. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother 1996;37(suppl A):27-39.
69. Thebault JJ, Montay G, Ebmeier A, Douin MJ, Millerioux L, Chassard D, et al. Effect of food on the bioavailability of the new fluoroquinolone sparfloxacin (abstract). In: Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, 1990:294.
70. Kinzig M, Pilz D, Naber KG, Sorgel F, Schugg C, Dehmlow C. Unique body fluid penetration of sparfloxacin (SPA) in man (abstract). In: Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992:182.
71. Mignot A, Douin MJ, Millerioux L, Chassard D, Thebault JJ, Montay G, et al. Effect of aluminum hydroxide antacid on the pharmacokinetics of the new quinolone sparfloxacin (abstract). In: Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, 1990:294.
72. Montay G, Bruno R, Vergniol JC, Rey J, Frydman A, Peeters PAM, et al. Pharmacokinetics of sparfloxacin after repeated administration in healthy elderly volunteers (abstract). In: Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1991:34.
73. Package insert. Levoquin (levofloxacin). Raritan, NJ: Ortho-McNeil Pharmaceutical Corporation, December 1996.
74. Holland ML, Chien SC, Corrado ML, Flor SC, Rogge MC. The pharmacokinetic profile of levofloxacin following once- or twice-daily 500 mg oral administration of levofloxacin hemihydrate. In: Selected Posters Presented at the Fifth International Symposium on New Quinolones, Singapore, 1994:38-9.
75. Chien S-C, Chow AT, Fowler CL, Williams RR, Callery-D'Amino S, Wong FA, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750 mg and 1 g doses of levofloxacin in healthy volunteers (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:3.
76. Holland ML, Chien SC, Corrado ML, Flor SC, Rogge MC. The pharmacokinetic profile of intravenous levofloxacin following once- or twice-daily 500 mg administration. In: Selected Posters Presented at the Fifth International Symposium on New Quinolones, Singapore, 1994:40-1.
77. Wise R, Child J, Mortiboy D, Chow AT. An open-label, cross-over study of the pharmacokinetics and tissue penetration of two dose regimens of levofloxacin (abstract). In: Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995:11.
78. Package insert. Zagam (sparfloxacin). Collegeville, PA: Rhône-Poulenc Rorer, December 1996.
79. Yamaguchi T, Yokogawa M, Sekine Y, Hashimoto M. Intestinal absorption characteristics of sparfloxacin. Xenobiotic Metab Dispos 1991;6:53-9.
80. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993;25:358-69.
81. Okazaki O, Kojima C, Hakusui H, Nakashima M. Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother 1991; 35:2106-9.
82. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94.
83. Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschhewski P, et al. Comparative pharmacokinetics of new quinolones. Drugs 1987;34 (suppl 1):21-5.
84. Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986;30:440-3.
85. Johnson JH, Cooper MA, Andrews JM, Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother 1992;36:2444-6.
86. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996;37(suppl A):57-63.
87. Nogita T, Ishibachi Y. The penetration of sparfloxacin into human plasma and skin tissue. J Antimicrob Chemother 1991;28:313-4.
88. Garcia I, Pascual A, Guzman MC, Perea EJ. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob Agents Chemother 1992;36:1053-6.
89. Child J, Mortiboy D, Andrews JM, Chow AT, Wise R. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 1995;39:2749-51.
90. Nakamori Y, Miyashita Y, Nakatani I, Nakata K. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 1995;49(suppl 2):418-9.
91. Garcia I, Pascual A, Salvador J, Conejo MC, Perea EJ. Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. J Antimicrob Chemother 1996; 38:859-63.
92. Pascual A, Garcia I, Perea EJ. Effect of antimicrobial agents on the uptake of ofloxacin and its optically active isomer (-)-ofloxacin hy human polymorphonuclear leucocytes. J Antimicrob Chemother 1991;28:727-30.
93. Pascual A, Garcia I, Perea EJ. Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob Agents Chemother 1990;34:277-80.
94. Yamaguchi T, Yokogawa M, Sakashita M, Itokawa A, Kurono M, et al. Metabolism of sparfloxacin in rats, dogs, monkeys and man. Xenobiotic Metab Dispos 1991;6:2132-4.
95. Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother 1994;38:733-7.
96. Mugnier P, Taburet AM, Wyld PJ, Nimmo WS, Hayes P, Grange D, et al. Pharmacokinetics of sparfloxacin in patients with hepatic failure (abstract). In: Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1994:19.
97. Tanigawara Y, Nomura H, Kagimoto N, Katsuhiko O, Hori R. Premarketing population pharmacokinetics study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull 1995; 18:315-20.
98. Rogge MC, Chien S-C, Wong F, Holland ML. Single-dose pharmacokinetics of levofloxacin: influence of age and gender. In: Selected Posters Presented at the Fifth International Symposium on New Quinolones, Singapore, 1994:44-5.
99. Gisclon LG, Curtin CR, Williams RR, Corrado ML, Rogge MC, Reichl V, et al. The pharmacokinetics of levofloxacin in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:3.
100. Aubier M, Geslin P, Regamey C, Verster R. Treatment of suspected pneumococcal community-acquired pneumonia: comparison of sparfloxacin and amoxicillin (abstract). In: Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993:307.
101. Lode H, Garau J, Grassi C, Hosie J. Treatment of community-acquired pneumonia: randomised comparison of sparfloxacin, amoxicillin-clavulanic acid and erythromycin. Eur Respir J 1995;8:1999-2007.
102. Portier H, May T, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxicillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37(suppl A): 83-91.
103. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C, Scandinavian Sparfloxacin Study Group. Oral empiric treatment of community-acquired pneumonia - multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996;110:1499-506.
104. Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther 1997;19:936-53.
105. Bensch G. Treatment of community-acquired pneumonia with sparfloxacin and erythromycin (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:282.
106. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
107. Fogarty CM. Noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of community-acquired pneumonia in adults. In: Clinical Update of the Latest Quinolone Research; Proceedings of the 19th International Congress of Chemotherapy, Montreal, 1995:66-7.
108. Miao J, Zhang G, Sun C, Zhang X. Clinical and pharmacokinetic studies of levofloxacin tablet of respiratory tract infections (abstract). In: Abstracts of the 19th International Congress of Chemotherapy, Montreal, 1995:443C.
109. DeAbate CA, Henry D, Bensch G, Jubran A, Chodosh S, Harper L, et al. Treatment of acute bacterial exacerbations of chronic bronchitis with sparfloxacin and ofloxacin (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:282.
110. Habib MP, Gentry LO, Rodriguez-Gomez G, Morowitz W, Williams RR. Multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:280.
111. DeAbate CA, Russel M, McElvaine P, Fowler CL. Multicenter, randomized study comparing levofloxacin and cefuroxime axetil in the treatment of acute bacterial exacerbations of chronic bronchitis (abstract). Clin Infect Dis 1996;23:914.
112. Sydnor TA, Scheid WM, Gwaltney JM. Noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of acute bacterial sinusitis in adults. In: Clinical Update of the Latest Quinolone Research. Proceedings of a CME symposium at the 19th International Congress of Chemotherapy, Montreal, 1995:72-3.
113. Adelglass J, DeAbate CA, McElvaine P, Fowler CL. Comparison of levofloxacin QD and amoxicillin-clavulanate TID for the treatment of acute bacterial sinusitis (abstract). Clin Infect Dis 1996;23:913.
114. Gehanno P, Berche P. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. J Antimicrob Chemother 1996;37 (suppl A):105-14.
115. Henry D, Moller D, Adelglass J, Scheid WM, Kraft C, Zhang H, et al. Treatment of acute bacterial maxillary sinusitis with sparfloxacin and clarithromycin (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:281.
116. Richard GA, Klimberg IN, Fowler C, Callery-D'Amico S. A combined analysis of two studies comparing levofloxacin with two other fluoroquinolones for the treatment of acute pyelonephritis (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:281.
117. Henry D, SPAR Multicenter UUTI Study Group. Treatment of community-acquired acute uncomplicated urinary tract infections (UUTI) with sparfloxacin (SPAR) and ciprofloxacin (CIP) (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:281.
118. Henry D, SPAR Multicenter UUTI Study Group. Treatment of community-acquired acute uncomplicated urinary tract infections (UUTI) with sparfloxacin (SPAR) and ofloxacin (OFL) (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:281.
119. Naber KG, Di Silverio F, Geddes A, Guibert J. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. J Antimicrob Chemother 1996;37(suppl A):135-44.
120. Moi H, Morel P, Gianotti B, Barlow D, Phillips I, Jean C. Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men. J Antimicrob Chemother 1996;37(suppl A):115-22.
121. Tanaka M, Matsumoto T, Kumazawa J, Nagayama A. Sparfloxacin in the treatment of males with urethritis. Eur J Clin Microbiol Infect Dis 1992;11:660.
122. Phillips I, Dimian C, Barlow D, Moi H, Stolz E, Weidner W, et al. A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1996;37(suppl A):123-34.
123. Takahasi H, Kukita A, Ishibasni Y, Asada Y, Arata J, Hori Y. A multicenter double blind comparative study of sparfloxacin and enoxacin in the treatment of skin and soft tissue infections (SSTI) (abstract). In: Program and Abstracts of the Thirty-First Interscience Conference Antimicrobial Agents Chemotherapy, Chicago, 1991:245.
124. Lipskt BA, for the Sparfloxacin Multicenter SSSI Study Group. Treatment of community-acquired complicated skin and skin structure infections with sparfloxacin and ciprofloxacin (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:282.
125. Nicodemo AC, Robledo JA, Jasovich A, Neto W. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of skin and skin structure infections (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:281.
126. Consensus Statement: therapeutic recommendations for community-acquired pneumonia and acute exacerbations of chronic bronchitis. Hosp Med 1997;33(2)(suppl):26-7.
127. Consensus Statement: summary diagnostic and therapeutic recommendations. Hosp Med 1997;33(2)(suppl):54-5.
128. Marutani K, Matsumoto M, Otabe Y, Matsubara S, Yokota T. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob Agents Chemother 1993;37:2217-23.
129. Matsumoto M, Kojima K, Nagano N, Matsubara S, Yokota T. Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation. Antimicrob Agents Chemother 1992;36: 1715-9.
130. Neringer R, Forsgren A, Hansson C, Ode B. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. Scand J Infect Dis 1992;24:773-80.
131. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996;37(suppl A):145-60.
132. Schaad UB. Use of the new quinolones in pediatrics. Isr J Med Sci 1994;30:463-8.
133. McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot Ankle Int 1996;17:496-8.
134. Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996;23:516-20.
135. Demolis L, Charransol A, Funck-Brentano C, Jaillon P. Effects of a single oral dose of sparfloxacin on ventricular depolarization in healthy volunteers. Br J Clin Pharmacol 1996;41:499-503.
136. Jaillon P, Morganroth J, Brumpt I, Talbot G, Sparfloxacin Safety Group. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996;37(suppl A):161-7.
137. Tanaka M, Kurata T, Fujisawa C, Ohshima Y, Aoki H, Okazaki O, et al. Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Antimicrob Agents Chemother 1993;37:2173-8.
138. Lee L-J, Hafkin B, Lee I-D, Hoh J. Effect of food and sucralfate on levofloxacin after a single oral dose of 500 mg in male and female subjects (abstract). In: Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995:8.
139. Zix JA, Geerdes-Fenge HF, Rau M, Koeppe P, Lode H. Sparfloxacin: interaction with sucralfate and cisapride (abstract). In: Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1996:2.
140. Kanemitsu K, Hori S, Yanagawa A, Shimada J. Effect of ferrous sulfate on the absorption of sparfloxacin in healthy volunteers and rats. Drugs 1995;49(suppl 2):352-6.
141. Gisclon LG, Curtin CR, Fowler CL, Nayak RK. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin (abstract). In: Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995:8.
142. Takagi K, Yamaki K, Nadai M, Kuzuya T, Hasegawa T. Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. Antimicrob Agents Chemother 1991;35:1137-41.
143. Liao S, Palmer M, Fowler CA, Nayak RK. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers (abstract). In: Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995:8.
144. Chien SC, Chow AT, Rogge MC, Williams RR, Hendrix C. Pharmacokinetics and safety of oral levofloxacin in HIV-infected individuals receiving concomitant zidovudine. Antimicrob Agents Chemother 1997;41:1765-9.
145. Furuhama K, Akahane K, Tawara K, Takayama S. Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice. Arzneimittelforschung 1992;42:406-8.
146. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 1990;26:219-25.
147. Iwamoto K, Ichikawa N, Naora K, Hirano H. Effect of fenbufen on the penetration of quinolone antibiotics into cerebrospinal fluid. Drugs 1995;49(suppl 2):349-51.
148. 1997 Drug topics red book. Montvale, NJ: Medical Economics, 1997.
149. Niederman MS, Bass JB Jr, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al., for the American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.